Skip to main content

Table 3 Relationship between the expression of AR, MMPs and TIMPs by each cellular type in breast cancer.

From: Androgen receptor expresion in breast cancer: Relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitors

Factor N AR score values median (range) p value
MMP-1    
TC (-) vs. (+) 7/104 0(0–70)/80(0–288) 0.004
FC (-) vs. (+) 14/97 2.5(0–225)/80(0–288) 0.03
MIC (-) vs. (+) 30/81 53(0–225)/81(0–288) n.s.
MMP-2    
TC (-) vs. (+) 70/41 59.5(0–279)/90(0–288) n.s.
FC (-) vs. (+) 83/28 69(0–288)/88(0–270) n.s.
MIC (-) vs. (+) 108/3 68.5(0–288)/66(0–132) n.s.
MMP-7    
TC (-) vs. (+) 8/103 0(0–156)/80(0–288) 0.01
FC (-) vs. (+) 27/84 68(0–267)/74.5(0–288) n.s.
MIC (-) vs. (+) 50/61 66(0–267)/81(0–288) n.s.
MMP-9    
TC (-) vs. (+) 27/84 48(0–270)/80.5(0–288) n.s.
FC (-) vs. (+) 93/18 68(0–288)/83.5(0–270) n.s.
MIC (-) vs. (+) 98/13 80(0–279)/30(0–288) n.s.
MMP-11    
TC (-) vs. (+) 11/100 8(0–168)/80(0–288) 0.03
FC (-) vs. (+) 33/78 53(0–264)/81(0–288) n.s.
MIC (-) vs. (+) 72/39 68(0–270)/87(0–288) n.s.
MMP-13    
TC (-) vs. (+) 29/82 48(0–225)/74.5(0–288) n.s.
FC (-) vs. (+) 54/57 56(0–267)/81(0–288) n.s.
MIC (-) vs. (+) 70/41 64.5(0–279)/92(0–288) n.s.
MMP-14    
TC (-) vs. (+) 10/101 64.5(0–273)/69(0–288) n.s.
FC (-) vs. (+) 21/90 92(0–273)/66.5(0–288) n.s.
MIC (-) vs. (+) 50/61 64.5(0–273)/81(0–288) n.s.
TIMP-1    
TC (-) vs. (+) 6/105 0(0–225)/72(0–288) n.s.
FC (-) vs. (+) 56/55 70(0–288)/69(0–273) n.s.
MIC (-) vs. (+) 81/30 64(0–279)/96(0–288) n.s.
TIMP-2    
TC (-) vs. (+) 13/98 0(0–174)/80(0–288) 0.01
FC (-) vs. (+) 59/52 80(0–270)/63(0–288) n.s.
MIC (-) vs. (+) 63/48 80(0–288)/68.5(0–279) n.s.
TIMP-3    
TC (-) vs. (+) 15/96 48(0–210)/76(0–288) n.s.
FC (-) vs. (+) 42/69 50.5(0–225)/88(0–288) n.s.
MIC (-) vs. (+) 53/58 64(0–279)/87(0–288) n.s.